Reported Sunday, Merck's Winrevair Demonstrates Statistically Significant 1.02 Wood Units Reduction In PVR In Phase 2 CADENCE Trial, Paving Way For Phase 3 Study

Merck's drug WINREVAIR achieved its primary endpoint in the Phase 2 CADENCE trial, demonstrating a statistically significant reduction of 1.02 Wood Units in pulmonary vascular resistance (PVR). The results, which indicate improved blood flow from the lungs to the heart, support advancing WINREVAIR into a Phase 3 registrational study, backed by comprehensive evidence across various clinical endpoints.